{"name":"Mologen AG","slug":"mologen-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MGN1703 treatment","genericName":"MGN1703 treatment","slug":"mgn1703-treatment","indication":"Colorectal cancer (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"MGN1703 treatment","genericName":"MGN1703 treatment","slug":"mgn1703-treatment","phase":"phase_3","mechanism":"MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.","indications":["Colorectal cancer (Phase 3)","Non-small cell lung cancer (Phase 2)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxOWnU3YnJCYzNuV0Y1RUFWQXpUYlFDTXhGa1hlMnhGRjAyRy01WXNJc05KSmd3RUVKZmV0aUxXWjVPbkV2dkhwb0s1NFdOWTRKSUVvYW8zdFNGSGJQSG5NMzFVQnB3WC12dS1ZQ3VPQnJ0a3pkVzdfTUlaMmV1bEp4VVJ1YS1QTmRBYlpJOGNYQ0c0M3VFcmZyeVhLTnJQcENYcmdkTHNWSmZiam45YlBwRVI0eHhJNkJPX0ZjdE1mZ2hOX0c5dVRNeUZtOU1LUzNpQjJhZ2NwNmpTQlBoSlh0VmpxbDBaWkZQX05YVmlvMFRzZXc2bnBRd2RrS3hNZFphTVhkT2hCc3BMUlliNHd3bXl3ZnJXa3M5NEFqR1ZNdHlERG_SAaMCQVVfeXFMTlp1N2JyQmMzbldGNUVBVkF6VGJRQ014RmtYZTJ4RkYwMkctNVlzSXNOSkpnd0VFSmZldGlMV1o1T25FdnZIcG9LNTRXTlk0SklFb2FvM3RTRkhiUEhuTTMxVUJwd1gtdnUtWUN1T0JydGt6ZFc3X01JWjJldWxKeFVSdWEtUE5kQWJaSThjWENHNDN1RXJmcnlYS05yUHBDWHJnZExzVkpmYmpuOWJQcEVSNHh4STZCT19GY3RNZmdoTl9HOXVUTXlGbTlNS1MzaUIyYWdjcDZqU0JQaEpYdFZqcWwwWlpGUF9OWFZpbzBUc2V3Nm5wUXdka0t4TWRaYU1YZE9oQnNwTFJZYjR3d215d2ZyV2tzOTRBakdWTXR5RERv?oc=5","date":"2026-02-04","type":"trial","source":"Bolsamania","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Bolsamania","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNVDFRcGxJVlFHSUJlTkk0SER6NnZqRFFYU1pRT1RWM2M0TllPeUFTMDk2QUlnYVZPVDRZSExCUEl6X2xwSVdQUDJ0UlFYRHFsbkFwVlVkbFNjeEloZFJiVWRkbmhyVmRoODBobjc4cHF3NzY2bU9xMFlVU0NYR1pISG5BR0IzUQ?oc=5","date":"2021-11-26","type":"pipeline","source":"EU-Startups","summary":"43 Top Biopharma Startups and Companies in Germany - EU-Startups","headline":"43 Top Biopharma Startups and Companies in Germany - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQMGh5VWdNclFnUGREMnl4UXIyYktBRGlzcDIwbnFiTm8zZDFUNzVaTlUyMU03VUlqNm42UzcyYXdHVG9ocjJCNTcwVWstNFluNHhnZzZwMVNRTEQ3Q1RGaE1XdjBmX3dMRkJEUEk1c3NBeVg0Z184OUVLd3B4STlURV81M2dBc3p1cXRsZ0JvRGNRZV93VW1XT0xRRUhJRTgtQ0Ezam1PdTBzbE9R?oc=5","date":"2016-05-11","type":"pipeline","source":"PMLiVE","summary":"Glycotope appoints Dr Alfredo Zurlo as chief medical officer - PMLiVE","headline":"Glycotope appoints Dr Alfredo Zurlo as chief medical officer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}